FDA Clears IMDx's MDx for Vancomycin-resistant Enterococci | GenomeWeb

NEW YORK (GenomeWeb News) – IntelligentMDx today announced it has received clearance from the US Food and Drug Administration for its molecular diagnostic test for vancomycin-resistant enterococci.

IMDx's assay detects the presence of vanA and vanB genes that have been associated with vancomycin-resistant enterococci, which are responsible for healthcare-related infections that include surgical wounds, urinary tract, and bloodstream infections.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.